From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
|Videos|November 8, 2021
How Specialty Pharmacies Can Support Palliative Care During Cancer Treatment
Jameshia Below, PharmD, an assistant professor of pharmacy practice at the University of Louisiana Monroe College of Pharmacy, explains how palliative care can support the cancer treatment process, and how specialty pharmacies can support this type of care.
Advertisement
Pharmacy Times interviewed Jameshia Below, PharmD, an assistant professor of pharmacy practice at the University of Louisiana Monroe College of Pharmacy, on her presentation at the 2021 National Pharmaceutical Association conference, titled Oncologic Emergencies: Recognition & Initial Management.
During this discussion, Below explained how palliative care can support the cancer treatment process, and how specialty pharmacies can support this type of care.
Advertisement
Related to this article
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with the rare airway disease.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
ESMO 2026 lung cancer trials reshape first-line care with tarlatamab maintenance, stronger KRAS G12C results, and TROP2 ADC gains, raising pharmacy monitoring demands.
ESMO 2026 breast cancer updates show ribociclib boosts survival, while immunotherapy and extended endocrine therapy improve end points without longer overall survival.
Every-12-week immune checkpoint inhibitor dosing failed to establish noninferiority in the phase 3 MOIO trial, with an overall survival imbalance and no meaningful safety advantage over standard treatment.
Six-year NATALEE data show adjuvant ribociclib (Kisqali) plus endocrine therapy improves overall survival in high-risk HR+/HER2- early breast cancer, with pharmacist-led monitoring.
Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
FDA Grants Accelerated Approval to First Plasmid DNA-Based Immunotherapy for Recurrent Respiratory Papillomatosis
3
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
4
Community Pharmacists Guide Patients New to Glucose Monitoring
5